Straits Times Index
3,290.70 +24.75 (+0.76%) Nikkei
38,229.11 +155.13 (+0.41%) Hang Seng
18,963.68 +425.87 (+2.30%) FTSE 100
8,433.76 +52.41 (+0.63%) Bitcoin USD
61,034.47 -1,679.66 (-2.68%) CMC Crypto 200
1,260.38 -97.63 (-7.19%)
AstraZeneca PLC (AZNCF)
| Previous close | 152.33 |
| Open | 156.62 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 156.01 - 156.62 |
| 52-week range | 118.16 - 159.12 |
| Volume | |
| Avg. volume | 4,679 |
| Market cap | 241.849B |
| Beta (5Y monthly) | 0.16 |
| PE ratio (TTM) | 37.59 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.86 (1.88%) |
| Ex-dividend date | 22 Feb 2024 |
| 1y target est | N/A |
- GlobeNewswire
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
Completion of the additional equity investment of $140M by AstraZeneca, as previously announced on November 1 and 15, 2023 NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that, following clearance from the French Ministry of Economy and satisfaction of all other closing conditions, AstraZeneca (LSE/STO/Nasda
- Business Wire
CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial
WILMINGTON, Del., May 02, 2024--Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with standard-of-care chemoimmunotherapy, bendamustine and rituximab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus standard of care in previously untreated adult patients with mantle cell lymphoma (MCL).
- Business Wire
AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio
WILMINGTON, Del., May 01, 2024--AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Society (ATS) International Conference, in San Diego, CA from May 17 - 22, 2024. The company will present 59 abstracts, including 12 late-breaking posters, with a focus on unmet needs in chronic obstructive pulmonary disease (COPD), severe asthma and eosinophilic granulomatosis with polyangiitis (EGPA), as
